Switzerland's inflation rate ticked up to 1.5% in October 2026, up from 1.0% the previous month, according to the Federal Statistical Office. The increase was driven by higher energy-related costs, including heating oil and fuel, as well as price rises for items like footwear and some medical services. The reading marks the highest inflation in nearly three years, as fuel costs continue to climb.
While the inflation data grabbed headlines, the bigger corporate story came from Lonza, a Swiss contract drug manufacturer. The company announced it has agreed to acquire five US contract development and manufacturing organization (CDMO) sites from Merck KGaA, a German science and technology company. The deal, which is expected to close in mid-2027, will expand Lonza's US footprint from four sites to nine.
What's behind the inflation rise?
Inflation in Switzerland has been relatively subdued compared to many other developed economies, but the recent uptick reflects broader global pressures on energy prices. Heating oil and fuel costs have been rising, and those increases are now showing up in consumer prices. The rise in footwear and medical services prices suggests that the inflation is not solely energy-driven, but also reflects broader demand and cost pressures.
For the Swiss National Bank (SNB), the inflation reading is a key input for its monetary policy decisions. The SNB has a mandate to keep inflation low and stable, typically targeting a rate below 2%. With inflation now at 1.5%, it remains within the bank's comfort zone, but the upward trend could influence expectations for future interest rate moves. If inflation continues to climb, the SNB might consider tightening policy, which could affect mortgage rates, savings returns, and the value of the Swiss franc.
For everyday investors, this means that Swiss mortgage rates could rise if the SNB responds to higher inflation, and savings accounts might offer slightly better returns. Conversely, a stronger franc could impact Swiss exporters, including companies like Lonza, by making their products more expensive for foreign buyers.
Lonza's US expansion: a strategic bet
Lonza's acquisition of five US manufacturing sites from Merck KGaA is a significant move in the contract manufacturing space. The company is paying a "low- to mid-triple-digit million" Swiss-franc enterprise valuation for the sites, which are part of Merck KGaA's CDMO business. The deal is expected to close in mid-2027, subject to regulatory approvals.
Lonza's management highlighted demand for bioconjugates and viral vectors, two fast-growing areas of modern medicine. Bioconjugates are drugs that combine a targeting molecule with a potent payload, often used in cancer therapies. Viral vectors are used in gene therapies and vaccines. Both require specialized manufacturing capabilities and are in high demand as pharmaceutical companies develop new treatments.
By acquiring existing sites, Lonza is betting that it can bring these facilities online faster than building new ones from scratch. In contract manufacturing, new capacity isn't just about physical infrastructure; it requires "tech transfer"—moving a customer's process into the plant—and regulatory qualification to ensure products can be sold. Buying ready-to-run sites can shorten that timeline, which is why Lonza is paying for existing facilities rather than building new ones.
What it means for investors
For Lonza's investors, the deal is a time-to-revenue bet. The acquisition is expected to close in mid-2027, and the benefits will likely take time to materialize. Once the sites are integrated and qualified, they could provide a steady stream of revenue from long-term contracts. In contract manufacturing, revenue tends to be stickier than in many industrial businesses because once a drug's manufacturing process has been validated for launch, switching suppliers can be slow and risky.
The market will likely focus on whether the deal improves Lonza's medium-term revenue visibility and its mix of higher-value commercial work. If the sites help Lonza meet demand in bioconjugates and viral vectors, the acquisition could be a significant growth driver. However, investors should also watch for integration risks and the potential for delays in regulatory approvals.
For the broader market, the deal highlights the ongoing consolidation in the CDMO sector, as companies seek to expand capacity to meet the growing demand for complex biologics. This trend could benefit other players in the space, but it also underscores the importance of scale and expertise in this specialized field.
In the near term, the inflation data and the Lonza deal are separate stories, but they both have implications for Swiss investors. Inflation could influence the SNB's policy, while Lonza's expansion is a bet on the future of drug manufacturing. Both are worth watching as 2027 approaches.
